A Five-Treatment-Period Study to Evaluate the Single-Dose Pharmacokinetics and Pharmacodynamics of Avatrombopag in Healthy Japanese and White Subjects
PHASE1CompletedINTERVENTIONAL
Enrollment
48
Participants
Timeline
Start Date
December 31, 2013
Primary Completion Date
June 30, 2014
Study Completion Date
September 30, 2014
Conditions
Thrombocytopenia
Interventions
DRUG
avatrombopag
Trial Locations (1)
Unknown
Parexel International Early Development Clinical Units, Glendale
All Listed Sponsors
lead
Eisai Inc.
INDUSTRY
NCT02039076 - A Five-Treatment-Period Study to Evaluate the Single-Dose Pharmacokinetics and Pharmacodynamics of Avatrombopag in Healthy Japanese and White Subjects | Biotech Hunter | Biotech Hunter